PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB): Results of Operations and Financial Condition
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 5 exhibit991-earningsrelease.htm EX-99.1 Document Exhibit 99.1 PacBio Announces Second Quarter 2026 Financial Results MENLO PARK, Calif., August 5, 2026 (GLOBE NEWSWIRE) – PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent
How this was made
The 30-second read
Why it matters
Traders can update models for FY 2026 revenue and near-term profitability given the explicit guidance range and the stated drivers of gross margin decline (compute/memory costs, Vega manufacturing transition, and lower Revio ASPs).
Market read
Fresh quarterly financials plus a new FY 2026 revenue range and margin driver commentary create a direct catalyst for PACB positioning into and after the earnings call.
What to watch
Investors may focus on the annualized Revio pull-through per system (~$202k vs ~$219k) and the mix shift from strategic multi-system placements, which can mask underlying demand strength until later quarters.
Background
PacBio filed an SEC 8-K with its Q2 2026 financial results (Exhibit 99.1) and included restructuring actions and operational milestones tied to SPRQ-Nx and Basecamp Research.
Ticker impact
PacBio reported Q2 2026 results and guided full-year 2026 revenue to $155 million to $165 million, plus noted SPRQ-Nx rollout and margin drivers.
Likely modest volatility around the guidance range and margin commentary, with direction dependent on how the market interprets the revenue outlook versus gross margin pressure.
Revenue was roughly flat year over year ($39.0M vs $39.8M) while gross margin declined (non-GAAP 38% to 36%), but the company also highlighted ongoing SPRQ-Nx commercialization and provided a specific FY 2026 revenue band.
Market effects
Signals ongoing execution in long-read sequencing commercialization (Revio/Vega placements, SPRQ-Nx chemistry rollout) while highlighting cost headwinds (compute/memory, manufacturing transition).
Primarily US-listed biotech/life-science equipment sentiment; limited direct regional spillover beyond investor perception of sequencing platform adoption.
Global rollout and publications in NEJM and Nature Genetics may support broader clinical credibility, but the immediate tradable driver is the company’s FY revenue guidance and margin trajectory.
Counterpoint
The revenue outlook ($155M to $165M) may be viewed as conservative if SPRQ-Nx pull-through accelerates slower than expected, especially with non-GAAP gross margin declining due to transition costs.
Key entities
- companyPacBio
NASDAQ-listed long-read sequencing company reporting Q2 2026 results and FY 2026 revenue guidance.
- product/programSPRQ-Nx chemistry
Sequencing chemistry rollout referenced as part of PacBio’s global commercial expansion.
- programBasecamp Research
AI therapeutic design lab for which PacBio began sequencing and sample delivery.
